Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aclidinium/formoterol fixed-dose combinations versus components and placebo in stable COPD
2011-001524-38Phase 3Completed
- Sponsor
- Almirall
- Start
- Jul 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of aclidinium and formoterol in chronic obstructive pulmonary disease (COPD) (5 arms), sponsored by Almirall. Primary endpoint: Co-primary efficacy variables. Started Jul 2011; status: completed.
02
Drugs
aclidiniumformoterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2011-001524-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001524-38.